LINE
Lineage, Inc. Common StockNASDAQREAL ESTATEREIT - INDUSTRIAL
Key Statistics
Market Cap
$8.14B
P/E Ratio
—
EPS
$-0.43
Beta
—
52W High
$55.57
52W Low
$30.81
50-Day MA
$37.07
200-Day MA
$38.71
Dividend Yield
6.47%
Profit Margin
-1.87%
Forward P/E
714.29
PEG Ratio
—
About Lineage, Inc. Common Stock
Lineage, Inc. (Ticker: LINE) is an innovative biotechnology company at the forefront of regenerative medicine, specializing in the development of advanced cell therapy solutions aimed at treating severe diseases such as eye disorders, spinal cord injuries, and cancer. Leveraging proprietary technologies and a strong commitment to strategic partnerships, the company is dedicated to revolutionizing patient care with its novel therapeutic approaches. As Lineage continues to enhance its diverse product pipeline and accelerate clinical research initiatives, it represents a compelling opportunity for institutional investors looking to support transformative advancements in healthcare.
Fundamentals
| Revenue (TTM) | $5.36B |
| Gross Profit (TTM) | $1.72B |
| EBITDA | $1.14B |
| Operating Margin | 5.17% |
| Return on Equity | -1.19% |
| Return on Assets | 0.81% |
| Revenue/Share (TTM) | $23.49 |
| Book Value | $36.33 |
| Price-to-Book | 0.91 |
| Price-to-Sales (TTM) | 1.52 |
| EV/Revenue | 2.877 |
| EV/EBITDA | 13.87 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -0.20% |
| Shares Outstanding | $227.08M |
| Float | $57.17M |
| % Insiders | 68.71% |
| % Institutions | 33.45% |
Analyst Ratings
Consensus ($41.37 target)
1
Strong Buy4
Buy12
Hold3
Strong SellData last updated: 4/8/2026